Key points
- FY25 revenue up 149.1% to $4,902,951
- Net loss after tax reduced by 87.8% to $1,463,310
- Company exited voluntary administration on 14 May 2025
- GeneType and AffinityDNA/EasyDNA businesses sold
- Auditor issued a qualified opinion due to administration period
Full summary
Genetic Technologies Ltd reported a preliminary final result for the year ended 30 June 2025, showing a substantial increase in revenue to $4,902,951, up 149.1% from the previous year. The company's net loss after tax was reduced by 87.8% to $1,463,310. The company exited voluntary administration on 14 May 2025 following the approval of a Deed of Company Arrangement (DOCA) by creditors. The geneType business and assets were sold to Rhythm Biosciences Limited, and the AffinityDNA and EasyDNA businesses were sold to Endeavor DNA, Inc. The financial statements have been audited by Hall Chadwick (NSW), which issued a qualified opinion due to the period of external administration.
Guidance
FY25 revenue: $4,902,951; Net loss after tax: $1,463,310
Outlook
The company's continuing viability is dependent on successful implementation of its recapitalisation strategy and securing additional funding.